Osteoporosis is one of the major health problems today, yet little is known about the loss of bone mass caused by reduced activity of the bone-forming osteoblasts. Here we show that mice deficient for the transcriptional cofactor four and a half LIM domains 2 (Fhl2) exhibit a dramatic decrease of bone mass in both genders. Osteopenia is caused by a reduced bone formation rate that is solely due to the diminished activity of Fhl2-deficient osteoblasts, while their number remains unchanged. The number and activity of the bone-resorbing cells, the osteoclasts, is not altered. Enforced expression of Fhl2 in differentiated osteoblasts boosts mineralization in cell culture and, importantly, enhances bone formation in transgenic animals. Fhl2 increases the transcriptional activity of runt-related transcription factor 2 (Runx2), a key regulator of osteoblast function, and both proteins interact in vitro and in vivo. In summary, we present Fhl2-deficient mice as a unique model for osteopenia due to decreased osteoblast activity. Our data offer a novel concept to fight osteoporosis by modulating the anabolic activity of osteoblasts via Fhl2.
Introduction
The maintenance of an overall constant bone mass is achieved by a balance between bone matrix deposition and mineralization effected by osteoblasts and resorption caused by osteoclasts (Karsenty and Wagner, 2002) . Bone loss is the outcome of imbalanced bone resorption relative to bone formation (Teitelbaum, 2000) . Although impaired bone formation contributes to the pathogenesis of osteoporosis, our knowledge of factors involved is limited. Characterization of the molecular mechanisms regulating bone formation is essential to understand the cause of osteoporosis. The runtrelated transcription factor 2 (Runx2) is a master regulatory gene of osteoblast differentiation Komori et al, 1997; Lee et al, 1997; Mundlos et al, 1997; Otto et al, 1997) , but also controls the activity of mature osteoblasts (Ducy et al, 1999) .
FHL2 is a member of the LIM-only subclass of the LIM protein superfamily. LIM proteins are defined by the presence of one or more LIM domains that mediate protein-protein interaction (Kadrmas and Beckerle, 2004) . The members of the FHL subclass of LIM-only proteins consist of four-and-ahalf LIM domains, exhibit a restricted expression pattern, and can function as transcriptional cofactors (Fimia et al, 2000; Mü ller et al, 2000; Labalette et al, 2004; Philippar et al, 2004; Yang et al, 2005) . FHL2 is highly expressed in the myocardium and in epithelial cells of the prostate (Chan et al, 1998; Mü ller et al, 2000) . FHL2 has been shown to act as a cofactor of several transcription factors, including androgen receptor (AR), CREB, AP-1, and SRF (Fimia et al, 1999; Müller et al, 2000; Morlon and Sassone-Corsi, 2003; Philippar et al, 2004) . In addition, FHL2 negatively regulates MAPK signaling in cardiomyocytes (Purcell et al, 2004) . FHL2 localizes to focal adhesions and translocates to the nucleus upon RhoA stimulation, thereby linking extracellular signals to gene expression (Mü ller et al, 2002) . Heart development and function of Fhl2-deficient mice is normal (Chu et al, 2000) , whereas in response to b-adrenergic stimulation Fhl2-deficient mice show a mild increase of heart hypertrophy (Kong et al, 2001) . So far, this is the only phenotype observed in Fhl2-deficient mice, although Fhl2 expression is not limited to heart. The present analysis uncovers Fhl2 expression in bone. Fhl2-deficient mice are osteopenic specifically due to decreased osteoblast activity. Conversely, enforced expression of Fhl2 in mature osteoblasts of transgenic mice results in increased bone mass and, consequently, Fhl2 regulates mineralization in a cell culture model system. On the molecular level, we show that Fhl2 interacts with Runx2 and functions as a transcriptional coactivator. Taken together, our data demonstrate a novel physiological function for Fhl2 and opens the path for the development of anabolic drugs that maintain bone mass through the regulation of Fhl2 activity in osteoblasts.
Results and discussion
Fhl2 is expressed in osteoblasts and Fhl2-deficient mice are osteopenic To investigate the potential effect of Fhl2 in bone, we analyzed Fhl2-deficient (Fhl2 À/À ) mice. The targeting strategy led to introduction of the b-galactosidase reporter under the control of the endogenous Fhl2 promoter (Kong et al, 2001) . We used this gene to demonstrate Fhl2 expression in bone in situ ( Figure 1A , top left). We detected staining of the bone collar (BC) region and the primary spongiosa (PS) of heterozygous mice, whereas no reporter gene expression was observed in growth plate cartilage ( Figure 1A , top left) and in C57BL/6 wild-type littermate controls ( Figure 1A , bottom left). The bone matrix is demarcated in black by von Kossa staining ( Figure 1A , top right) and bone-resorbing cells are stained by Trap ( Figure 1A , bottom right, arrows). Since the BC is devoid of osteoclasts, this pattern of expression suggests that Fhl2 is expressed in bone-forming osteoblasts.
We performed histological analysis of bones of Fhl2 À/À mice at the age of 1 week, 1, 3, 6, and 9 months. Von Kossa staining, radiography, and micro-computed tomography analysis demonstrate that bone mass is progressively lost compared to wild-type control mice, leading to an osteopenic phenotype ( Figure À/À mice. Fhl2 À/À mice, 9-month old, show a marked reduction in bone mass by 32% compared to age-and sexmatched C57BL/6 wild-type control animals ( Figure 1C ). Bone loss is reflected by a decrease in trabecular thickness and an increase in trabecular spacing in Fhl2 À/À mice compared to control animals ( Figure 1D and E). Taken together, both female and male Fhl2 À/À mice exhibit osteopenia to the same extent ( Figure 1C -E).
Bone formation rate is reduced in Fhl2
To analyze the mechanism of Fhl2 action, we first demonstrated that the number of osteoblasts and osteoclasts relative to the bone volume in Fhl2 À/À mice was not altered in comparison to C57BL/6 control littermates ( Figure 2A ). We then determined bone resorption in vivo by measurement of pyridinium crosslinks in urine samples. Pyridinium crosslinks are a degradation product of bone resorption released into the circulation and hence directly mirror osteoclast activity (Robins et al, 1991) . As shown in Figure 2B , osteoclast activity is not affected in Fhl2 À/À mice. Next, the bone formation rate was determined in vivo by incorporation of calcein into the bone matrix after double injection. The distance between the calcein labels is reflecting osteoblast activity. Importantly, we show that the bone formation rate is reduced by 24% in Fhl2 À/À mice ( Figure 2C and D Figure 2) . Taken together, our data suggest that the osteopenic phenotype of Fhl2 À/À mice is due to decreased osteoblast function.
Fhl2 expression in osteoblasts regulates bone formation
To further verify that Fhl2 increases bone formation rate by modulation of osteoblast activity in vivo, we generated transgenic FVB mice expressing Fhl2 specifically in either mature osteoclasts or osteoblasts. Enforced expression of Fhl2 in osteoblasts results in an increase in bone mass in the transgenic animals by 27% compared to FVB wild-type littermates ( Figure 3A and B). The gain in bone mass is caused by an increase in osteoblast activity reflected by an enhanced bone formation rate. Osteoblast and osteoclast numbers remain unchanged (Supplementary Figure 4) . In contrast, transgenic mice that express Fhl2 in osteoclasts neither show a change in bone mass and bone formation rate, nor in osteoclast and osteoblast number ( Figure 3A and further support the idea that the osteopenia in Fhl2
animals is caused by reduced osteoblast activity.
To investigate the consequences of Fhl2 deficiency on the cellular level, we prepared primary osteoblast cultures derived from calvaria of C57BL/6 wild-type and Fhl2 À/À mice.
Deposition of extracellular matrix was monitored by alizarin red S staining after 17 days in mineralization medium. Importantly, areas of mineralized matrix are reduced in If Fhl2 deficiency is the cause for reduced expression of genes responsible for osteoblast activity and, consequently, for a lower bone formation rate, then augmented Fhl2 expression should lead to both an increment of marker gene expression and calcified extracellular matrix. To address this issue, we stably transfected the mature osteoblast cell line 7F2 (Thompson et al, 1998 ) with a myc-tagged Fhl2 expression plasmid (7F2-Fhl2). In comparison to control cells, 7F2-Fhl2 cells exhibit a clear three-fold increase in calcified extracellular matrix already after 12 days in mineralization medium ( Figure 3D and E) . Moreover, qRT-PCR analyses demonstrate that elevated Fhl2 expression in 7F2 cells results in increased levels of osteoblast marker genes such as osteocalcin 2 (Oc) and Phex ( Figure 3F ), which are specific for osteoblast activity (Guo and Quarles, 1997; Karsenty and Wagner, 2002) . In contrast, expression of alkaline phosphatase 2 (Akp2) reflecting osteoblast differentiation (Aubin et al, 1995) is not altered ( Figure 3F ). Conversely, we reduced endogenous Fhl2 expression in 7F2 cells by a retroviral-based RNA interference (siRNA). 7F2 cells stably expressing siRNA directed against Fhl2 (7F2-siRNA Fhl2) show reduced calcified extracellular matrix formation by 48% after 12 days in mineralization medium compared to the control cell line expressing an unrelated siRNA ( Figure 3E ). Marker gene expression is reduced accordingly (data not shown). Fhl2 expression levels in 7F2-Fhl2 as well as in the Fhl2 knockdown cells were verified by RT-PCR ( Figure 3E ). Taken together, these results demonstrate that the phenotype caused by altered Fhl2 expression is cell autonomous and that Fhl2 modulates osteoblast activity.
Fhl2 interacts with Runx2 and enhances the transcriptional activity of Runx2
To date, little information is available about the molecular mechanisms regulating the activity of differentiated osteoblasts in vivo. It is well known that Fhl2 can increase the transcriptional activity of the androgen receptor (AR; Mü ller et al, 2002). To evaluate a possible involvement of the AR in the osteopenia caused by Fhl2 deficiency, mice were continuously treated with 5a-dihydrotestosterone over a period of 4 weeks. Fhl2 À/À and C57BL/6 wild-type control animals exhibit an increase in bone mass in an equal ratio (data not shown). These data, together with the observations that both female and male Fhl2 À/À mice exhibit osteopenia to the same extent (Figure 1 ), suggest that the interaction of Fhl2 with AR does not contribute to the observed osteopenia. Runx2 is known to play a major role in osteoblast function (Ducy, 2000) . To demonstrate a possible interaction between Fhl2 and Runx2 in vitro, we performed pulldown experiments with bacterially expressed GST-Fhl2, various mutants thereof, and 35 S-methionine-labeled Runx2 ( Figure 4A ). Runx2 interacts with full-length Fhl2 and the C-terminal LIM domains 3 and 4, but neither with LIM domains 0-2 nor the GST control protein. To determine which region of Runx2 binds to Fhl2, a series of mutant Runx2 proteins was tested ( Figure 4B) . Deletion of the Runx2 N-terminus containing activation domains 1 and 2 does not impair binding to Fhl2. Instead, the region containing the RUNT domain as well as the C-terminal activation domain 3 and the repression domain facilitates interaction with Fhl2 ( Figure 4B ).
To corroborate the interaction between Fhl2 and Runx2 in vivo, GST-Fhl2 and Runx2 were expressed in 293 cells. The GST-Fhl2/Runx2 complex was efficiently formed in vivo and immobilized on GT-sepharose ( Figure 4C ). Runx2 was not found in complexes using GST-transfected control extracts, thus demonstrating specificity ( Figure 4C ).
To further validate association of Fhl2 and Runx2 in vivo, 7F2 and primary osteoblast cells were subjected to chromatin immunoprecipitation (ChIP). The Oc promoter was chosen because it contains two Runx2-binding sites (OSE2; Ducy and Karsenty, 1995) . As shown in Figure 4D , genomic DNA corresponding to the proximal Runx2-binding site of the osteocalcin promoter was specifically immunoprecipitated with either a-Runx2 or a-Fhl2 antibodies. Genomic DNA derived from the U6 promoter was not enriched, thus demonstrating specificity ( Figure 4D ). To further demonstrate that Fhl2 and Runx2 form a complex on the chromatinized osteocalcin promoter, 7F2 cells and primary osteoblasts were subjected to sequential ChIP (Re-ChIP), first with an a-Fhl2 antibody and next with either a-Runx2 or control rabbit IgG. Importantly, the osteocalcin promoter was specifically enriched in an Fhl2-dependent manner, demonstrating that Fhl2 and Runx2 form a protein complex on the chromatinized osteocalcin promoter in vivo ( Figure 4D and Supplementary Figure 5 ). In conclusion, this set of experiments demonstrates association of Fhl2 and Runx2 both in vitro and in vivo.
To examine the potential regulation of Runx2 by Fhl2 on a naturally occurring gene, the Oc promoter was analyzed because Runx2 is known to regulate Oc expression specifically in mature osteoblasts (Ducy and Karsenty, 1995) . As shown in Figure 4E , coexpression of Fhl2 and Runx2 significantly enhances reporter gene activity. Mutations in the two OSE2 sites abolishing Runx2 binding result in a reporter that is neither responsive to Runx2 (Ducy and Karsenty, 1995) nor Fhl2 ( Figure 4E ). Consequently, mutants of Fhl2, that do not interact with Runx2 ( Figure 4A ), also fail to coactivate reporter gene expression ( Figure 4F ).
In summary, our data show for the first time the osteopenic phenotype of Fhl2 À/À mice and unravel the underlying mechanism. We postulate that Fhl2 is a major regulator of osteoblast function since Fhl2 À/À mice exhibit decreased osteoblast activity, while transgenic mice with enforced Fhl2 expression in mature osteoblasts display increased bone mass. Moreover, we show that Fhl2 functionally interacts with Runx2, a regulator of osteoblast activity (Ducy et al, 1999) . To our knowledge, the Fhl2-deficient mouse is the first animal model that exhibits osteopenia caused by a permanently decreased activity of osteoblasts. Thus, modulation of Fhl2 function by pharmacological intervention offers a novel strategy to prevent bone loss by increasing the anabolic activity of osteoblasts.
Materials and methods

Transgenic mice and histomorphometry
All animals were housed in the pathogen-free barrier facility of the Zentrale Klinische Forschung, Universitätsklinikum Freiburg in accordance with institutional guidelines and approved by the regional board. Fhl2 À/À mice were bred to a congenic C57BL/6 background (11 or more generations). Transgenic mice were generated by pronuclear injection into the fertilized eggs of FVB mice using standard procedures. Osteoblast-and osteoclast-specific expression of Fhl2 was driven by a 1.3 kb fragment of the Oc promoter (Frendo et al, 1998) and a 1.8-kb fragment of tartrateresistant acid phosphatase promoter (Boyce et al, 1995) , respectively. Specificity of transgene expression was verified by RT-PCR in three independent lines. Histomorphometry was performed on age-and sex-matched congenic mice (nX3 for each age and gender) as described (Ducy et al, 1999) . Cryosections of hind legs from 3-day-old mice were incubated for 24 h at 371C in the dark with buffered X-gal staining solution (Sigma), dehydrated, and mounted. Von Kossa stain was performed as described . Trap stain (Sigma) was performed according to the manufacturer. Mineralization in cell lines was quantified using ImageJ (NIH). All experiments and measurements were repeated at least three times.
Serum markers and proliferation assay
Untreated serum components were analyzed according to the manufacturers: calcium (Sigma) and phosphate (Sigma) related to standards (Randox), intact PTH (ELISA, Immunotopics), 25-hydroxyvitamin D (chemiluminescence assay, Nichols Advantage), alkaline phosphatase activity (Wako), testosterone (RIA, Diagnostic System Laboratories), 17b-estradiol (RIA, Adaltis). Alkaline phosphate activity was related to the protein content of serum or cell extracts using Bradford reagent (BioLabs). Measurement of pyridinium crosslinks (EIA, Quidel) was performed according to the manufacturer and related to total urinary creatinine content (Quidel). Proliferation of primary osteoblasts was determined according to the manufacturer (ELISA, Roche). 10 4 cells/well were seeded in 96-well plates. After 24 h, BrdU was added to the culture medium for 20 h. The analysis was replicated three times with 30 wells for each genotype.
Plasmids
The following plasmids were described: CMX-Fhl2, GST-Fhl2 and mutants thereof (Mü ller et al, 2002) , pCMV-Osf2 (Ducy and Karsenty, 1995) , Oc-Luc, and DOc-Luc (Koeneman et al, 1999) . To construct the CMX-Runx2 deletion mutants, the corresponding fragments (AD1 þ AD2, amino acids 1-102; RUNT, amino acids 104-364; AD3 þ RD, amino acids 347-528) were amplified by PCR and inserted at the NheI restriction site of CMX. pIRES-myc-Fhl2-bsd was generated by insertion of myc-Fhl2 cDNA at the HindIII/ BamHI restriction sites of pIRES-bsd. All plasmids were verified by sequencing.
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Cell culture and transfections
Primary cells, MG-63, 7F2, and 293 cells were cultured in a-MEM (Cambrex) and DMEM (Cambrex) supplemented with 10% fetal calf serum. Stable 7F2 cell lines, transfected with pIRES-myc-Fhl2-bsd or control plasmid pIRES-bsd, were selected by addition of 10 ng/ml blasticidin (Invitrogen). 293 cells were transfected with calcium phosphate, MG-63, and 7F2 cells using Effectene (Qiagen; Mü ller et al, 2000; Metzger et al, 2003) . Transient transfection assays were carried out in 24-well plates with 5 Â10 4 cells/well. The total amount of transfected DNA was kept constant (375 ng/well) using 250 ng reporter, 50 ng Runx2, and 15 ng Fhl2 expression plasmids, and the corresponding amounts of empty vectors. Luciferase activity was assayed as described (Mü ller et al, 2000; Metzger et al, 2003) . All experiments were replicated at least seven times in duplicate. Primary cells were derived from 3-to 5-day-old mice as described (Ducy et al, 1999) . Starting at confluence, medium was supplemented with 5 mM glycerol 2-phosphate (Sigma) and 100 mg/ ml 2-phospho-L-ascorbic acid (Fluka) every second day for mineralization assays. Primary osteoblasts were infected with a Runx2-expressing retrovirus (pTJ66-Runx2) or the corresponding control virus (Byers et al, 2002) .
Interactions assays and Western blot analysis
Interaction analyses in vitro and in vivo were performed as described (Mü ller et al, 2000; Metzger et al, 2003) . EMSAs were performed as described (Ducy and Karsenty, 1995) , with oligonucleotides containing either wild-type (OSE2) or mutant (OSE2mt) Runx2-binding sites. In all, 10 mg of a-Cbfa1 or M2 (Sigma) was used. Western blots were decorated with a-Fhl2 (1:2000) and a-Runx2 (Santa Cruz, 1:500).
Chromatin immunoprecipitation
ChIP experiments were performed essentially as described using 7F2 cells and primary osteoblasts derived from wild-type mice (Shang et al, 2002) . Immunoprecipitation was performed with specific antibodies (a-Cbfa1, a-Fhl2) on GammaBind TM -Sepharose 4B (GE-Healthcare). For PCR, 1-5 ml out of 50 ml DNA extract was used. For Re-ChIP assays, immunoprecipitations were sequentially washed with TSE I, TSE II, buffer III, and TE (Shang et al, 2002) . Complexes were eluted by incubation with 10 mM DTT at 371C for 30 min, diluted 50 times with dilution buffer (Shang et al, 2002) , followed by a second immunoprecipitation with the indicated antibody. Primer sequences were as follows:
Oc promoter: 5 0 -AGTCTCCGATTGTGGCCTCT-3 0 ; 5 0 -CCTCCAGCATCCAGTAGCAT-3 0 ; U6 promoter: 5 0 -CACAGACTTGTGGGAGAAGC-3 0 ; 5 0 -GGGTGAGTTTCCTTTTGTGC-3 0 .
Fhl2 knockdown
The siRNA directed against Fhl2 was constructed with the Silencer Express (human H1) siRNA Expression Cassette kit (Ambion) and subcloned into the lentiviral vector pLV-THM. pLV-THM expressing an unrelated siRNA (#62) served as a control (http://www.tronolab.unige.ch/). Sequences for Fhl2 siRNA can be obtained upon personal request.
qRT-PCR and statistical analysis
DNAseI-treated RNA isolated using RNAwiz (Ambion) was used for reverse transcription. Quantitative PCR was performed in an ABI PRISM 7700 sequence detector. Product formation was detected by incorporation of SYBR Green I using ROX as a passive reference (ABgene). The expression ratios of the analyzed cDNAs were related to the normalized C p of the housekeeping gene Hprt in control and sample. Experiments were repeated at least three times.
The following primers were used:
Akp2 Statistical analysis for qPCR was performed by group-wise comparison based on PCR efficiencies and the mean crossing point deviation between the sample and control group using the Relative Expression Software Tool (Pfaffl et al, 2002) . The t-test was used for all other analyses.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
